For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
The goal of this clinical research study is to learn if SGI-110 can help to control MDS. The safety of this drug will also be studied.
Sat, 11/01/2014 to Fri, 11/01/2019
Drug: SGI-110 60 mg/m2 subcutaneously daily for 5 days every 4 weeks.